Literature DB >> 8376318

Effects of tumor necrosis factor and interferon-beta on proliferation and epidermal growth factor binding in young and senescent WI-38 cells.

F L Cianciarulo1, P D Phillips, V J Cristofalo.   

Abstract

Tumor necrosis factor-alpha (TNF) and various interferons (IFN) have potent cytostatic or cytotoxic effects on a variety of human tumor-derived cell lines. Their effects on normal cells are more controversial. We have examined the effects of TNF and IFN-beta on the proliferation of WI-38 cells in a serum-free, growth factor-supplemented medium and in serum-containing medium. These cells respond to the combination of epidermal growth factor (EGF), insulin-like growth factor-I (IGF-I), and dexamethasone by DNA synthesis at a rate and extent equivalent to serum-stimulated cells. TNF has no effect on this growth factor-stimulated proliferation. However, it is stimulatory in serum-containing medium. IFN-beta inhibits DNA synthesis 60 to 70% in both young and senescent cells. TNF and IFN-beta together have a synergistic effect and completely inhibit growth factor-stimulated DNA synthesis in young cells. No synergism was observed with senescent cells. TNF stimulated an increase in the number of EGF specific binding sites two- to threefold in 24 h in both young and senescent cells. This seems to result from a proportional increase in a very high affinity binding site. IFN-beta has little or no effect on EGF binding either alone or in combination with TNF.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8376318     DOI: 10.1007/bf02634555

Source DB:  PubMed          Journal:  In Vitro Cell Dev Biol Anim        ISSN: 1071-2690            Impact factor:   2.416


  17 in total

1.  Classification system based on the functional equivalency of mitogens that regulate WI-38 cell proliferation.

Authors:  P D Phillips; V J Cristofalo
Journal:  Exp Cell Res       Date:  1988-04       Impact factor: 3.905

2.  Stimulation by transforming growth factor-beta of epidermal growth factor-dependent growth of aged human fibro-blasts: recovery of high affinity EGE receptors and growth stimulation by EGF.

Authors:  T Kawamoto; M Nishi; K Takahashi; T Nishiyama; J D Sato; S Taniguchi
Journal:  In Vitro Cell Dev Biol       Date:  1989-10

3.  An endotoxin-induced serum factor that causes necrosis of tumors.

Authors:  E A Carswell; L J Old; R L Kassel; S Green; N Fiore; B Williamson
Journal:  Proc Natl Acad Sci U S A       Date:  1975-09       Impact factor: 11.205

4.  Growth regulation of WI38 cells in s serum-free medium.

Authors:  P D Phillips; V J Cristofalo
Journal:  Exp Cell Res       Date:  1981-08       Impact factor: 3.905

5.  Dexamethasone inhibits feedback regulation of the mitogenic activity of tumor necrosis factor, interleukin-1, and epidermal growth factor in human fibroblasts.

Authors:  M Kohase; D Henriksen-Destefano; P B Sehgal; J Vilcek
Journal:  J Cell Physiol       Date:  1987-08       Impact factor: 6.384

6.  Tumor necrosis factor acts synergistically with autocrine interferon-beta and increases interferon-beta mRNA levels in human fibroblasts.

Authors:  L F Reis; T Ho Lee; J Vilcek
Journal:  J Biol Chem       Date:  1989-10-05       Impact factor: 5.157

7.  Tumor necrosis factor increases the number of epidermal growth factor receptors on human fibroblasts.

Authors:  V J Palombella; D J Yamashiro; F R Maxfield; S J Decker; J Vilcek
Journal:  J Biol Chem       Date:  1987-02-15       Impact factor: 5.157

8.  Molecular weight of recombinant human tumor necrosis factor-alpha.

Authors:  T Arakawa; D A Yphantis
Journal:  J Biol Chem       Date:  1987-06-05       Impact factor: 5.157

9.  [125I]EGF binding ability is stable throughout the replicative life-span of WI-38 cells.

Authors:  P D Phillips; E Kuhnle; V J Cristofalo
Journal:  J Cell Physiol       Date:  1983-03       Impact factor: 6.384

10.  Fibroblast growth enhancing activity of tumor necrosis factor and its relationship to other polypeptide growth factors.

Authors:  J Vilcek; V J Palombella; D Henriksen-DeStefano; C Swenson; R Feinman; M Hirai; M Tsujimoto
Journal:  J Exp Med       Date:  1986-03-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.